Page last updated: 2024-08-07 10:12:13
Gag-Pol polyprotein
A lentivirus-type gag-pol polyprotein that is encoded in the genome of Human immunodeficiency virus type 1 group M subtype B (isolate BRU/LAI). [PRO:DAN, UniProtKB:P03367]
Synonyms
Pr160Gag-Pol
Research
Bioassay Publications (14)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 13 (92.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Compounds (19)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| kynostatin 272 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0009 | 1 | 8 |
| nelfinavir | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0146 | 3 | 15 |
| amprenavir | Human immunodeficiency virus type 1 (BRU ISOLATE) | IC50 | 0.0270 | 1 | 1 |
| amprenavir | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0032 | 4 | 9 |
| dmp 323 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0003 | 1 | 1 |
| lopinavir | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0017 | 1 | 6 |
| atazanavir | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0006 | 1 | 6 |
| dmp 450 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0003 | 1 | 1 |
| uic-94003 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0000 | 2 | 2 |
| darunavir | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0013 | 3 | 8 |
| ritonavir | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0043 | 3 | 15 |
| xv 638 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0000 | 1 | 1 |
| saquinavir | Human immunodeficiency virus type 1 (BRU ISOLATE) | IC50 | 0.0160 | 1 | 1 |
| saquinavir | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0109 | 2 | 7 |
| xk 263 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0003 | 1 | 1 |
| je 2147 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0001 | 1 | 8 |
| mvt 101 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 12.1175 | 1 | 4 |
| l 739594 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0020 | 1 | 1 |
| grl 02031 | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0001 | 1 | 1 |
| indinavir sulfate | Human immunodeficiency virus type 1 (BRU ISOLATE) | IC50 | 0.0004 | 1 | 1 |
| indinavir sulfate | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0749 | 5 | 25 |
| l 682679 | Human immunodeficiency virus type 1 (BRU ISOLATE) | IC50 | 0.0006 | 1 | 1 |
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.Biochemistry, , May-02, Volume: 45, Issue:17, 2006
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.Biochemistry, , Dec-30, Volume: 42, Issue:51, 2003
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.Bioorganic & medicinal chemistry letters, , Jun-05, Volume: 10, Issue:11, 2000
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.Journal of medicinal chemistry, , Oct-09, Volume: 51, Issue:19, 2008
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.Biochemistry, , May-02, Volume: 45, Issue:17, 2006
Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 15, Issue:15, 2005
Optimization of pyrrolidinone based HIV protease inhibitors.Bioorganic & medicinal chemistry letters, , Jan-03, Volume: 15, Issue:1, 2005
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.Bioorganic & medicinal chemistry letters, , Jun-05, Volume: 10, Issue:11, 2000
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.Journal of medicinal chemistry, , Dec-10, Volume: 52, Issue:23, 2009
Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy.Bioorganic & medicinal chemistry letters, , Aug-05, Volume: 12, Issue:15, 2002
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.Journal of medicinal chemistry, , Dec-10, Volume: 52, Issue:23, 2009
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.Journal of medicinal chemistry, , Aug-24, Volume: 49, Issue:17, 2006
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.Journal of medicinal chemistry, , Feb-23, Volume: 49, Issue:4, 2006
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.Biochemistry, , May-02, Volume: 45, Issue:17, 2006
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.Biochemistry, , Dec-30, Volume: 42, Issue:51, 2003
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.Bioorganic & medicinal chemistry letters, , Jun-05, Volume: 10, Issue:11, 2000
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.Journal of medicinal chemistry, , Oct-09, Volume: 51, Issue:19, 2008
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.Biochemistry, , May-02, Volume: 45, Issue:17, 2006
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.Bioorganic & medicinal chemistry letters, , Jun-05, Volume: 10, Issue:11, 2000
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.Biochemistry, , May-02, Volume: 45, Issue:17, 2006
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.Journal of medicinal chemistry, , Feb-23, Volume: 49, Issue:4, 2006
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.Journal of molecular biology, , Dec-09, Volume: 354, Issue:4, 2005
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.Biochemistry, , Dec-30, Volume: 42, Issue:51, 2003
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.Journal of medicinal chemistry, , May-08, Volume: 46, Issue:10, 2003
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.Bioorganic & medicinal chemistry letters, , Jun-05, Volume: 10, Issue:11, 2000